Dainippon Sumitomo Pharma has obtained manufacturing and marketing approval for Zolpidem tartrate tablets 5mg/10mg [DSP] from the Ministry of Health, Labour and Welfare in Japan. Zolpidem tartrate tablets 5mg/10mg [DSP] are film-coated tablets containing 5mg or 10mg of zolpidem tartrate, with a score line on one side, which are indicated for the treatment of Insomnia. The usual adult dose is once daily 5 to 10mg of zolpidem tartrate administered orally immediately before bedtime, the company said. The initial dose for elderly patients is from 5mg once daily and may be adjusted depending on age, symptoms, disease, and should not exceed 10mg once daily.
Dainippon wins manufacturing approval for sleep inducing therapy in Japan
Related stories
Press Releases
New Syngene biologics manufacturing facility to be operational for US and European customers from mid-year
At DCAT 2024 global bio/pharmaceutical manufacturing forum, Syngene International,...
News
ST Pharm breaks ground on 2nd oligonucleotide manufacturing plant
ST Pharm said it has taken its first step...
BioPharma
Elevating Biopharmaceutical Projects With The Right CDMO
In the biopharma industry, selecting the right contract development...
News
Biovian announces over €50 million investment in manufacturing facility in Turku, Finland
Biovian, a leading contract development and manufacturing organization (CDMO)...
News
New PAT – Based Strategy Stops Membrane Fouling In SP – TFF
A recent article published in the Journal of Membrane...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Latest stories
Previous article